Cytokine Filtration in Lung Transplantation - a Randomised, Controlled, Multicentre Clinical Trial (GLUSorb)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 116
- 试验地点
- 2
- 主要终点
- To determine whether cytokine reduction by cytokine filtration leads to improved oxygenation in patients undergoing lung transplantation.
研究概览
简要总结
Lung transplantation (LTx) remains the gold standard for treating patients with irreversible end-stage pulmonary disease. Of the major organs transplanted, survival in LTx recipients remains the lowest (mean 5 years). Despite improvements, primary graft dysfunction (PGD), as defined by respiratory insufficiency and edema up to 72 hours post LTx, remains the leading cause of early mortality and contributes to the development of chronic lung allograft dysfunction (CLAD) which is the leading cause of late mortality. PGD develops within the first 72 hours after LTx. The development of CLAD increases quickly with cumulative incidence of 40-80 % within the first 3-5 years. There is a general lack of efficient treatments for PGD and CLAD. Prevention of PGD is therefore of crucial importance and has a direct impact on survival.
The present study is a randomized controlled study which aims to compare patients undergoing LTx with and without the utilization of cytokine adsorption.
详细描述
Early intolerance to the newly transplanted lung starts at the time of transplantation and results in PGD driven by an intense inflammatory response. Cytokines play a critical role as signaling molecules that initiate, amplify, and maintain inflammatory responses both locally and systemically. The use of cytokine filtration devices to target middle- and low-molecular weight molecules has been shown to reduce levels of a diverse number of cytokines. These results have been demonstrated in the in vitro reduction of pathogen-associated molecular pattern molecules (PAMPS) and damage associated molecular patterns (DAMPS) as well as in in vivo studies involving orthotopic heart transplantation and kidney transplantation. Cytokine adsorption has been used successfully in clinical applications to both heart and kidney transplantation.
The present study is a randomized controlled study which aims to collect preliminary data on the efficacy of a medical device through the comparison of patients undergoing LTx with and without cytokine adsorption.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligibility to undergo double lung transplantation at either trial site
排除标准
- •Age <18 years
- •Previous organ transplantation
- •Presence of any conditions at the time of surgery that require immunosuppressive therapy. Immunosuppressive therapy is defined as:
- •Cyclosporine, Tacrolimus, Everolimus, or Sirolimus, minimum 1 month of treatment prior to transplantation and active treatment at the time of transplantation.
- •Any form of antibody-based treatment that is known for having an immunomodulatory effect taken up to 1 week before transplantation.
- •Non-consent
结局指标
主要结局
To determine whether cytokine reduction by cytokine filtration leads to improved oxygenation in patients undergoing lung transplantation.
时间窗: First 72 hours after lung transplantation
Higest value of oxygenation expressed as the PaO2/FiO2 ratio.
To determine whether cytokine reduction by cytokine filtration leads to improved oxygenation in patients undergoing lung transplantation. Oxygenation at 24 hours
时间窗: 24 hours after lung transplantation
Oxygenation expressed as the PaO2/FiO2 ratio at 24 hours
To determine whether cytokine reduction by cytokine filtration leads to improved oxygenation in patients undergoing lung transplantation. Oxygenation at 72 hours
时间窗: 72 hours after lung transplantation
Oxygenation expressed as the PaO2/FiO2 ratio at 72 hours
To determine whether cytokine reduction by cytokine filtration leads to improved oxygenation in patients undergoing lung transplantation. Oxygenation at 48 hours
时间窗: 48 hours after lung transplantation
Oxygenation expressed as the PaO2/FiO2 ratio at 48 hours
次要结局
- To determine whether cytokine reduction by cytokine filtration improves arterial blood gas measures in patients undergoing lung transplantation(0-72 hours (0-3 days) after lung transplantation)
- To determine whether cytokine reduction by cytokine filtration decreases mortality in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration improves quality of life (QOL) in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration decreases need for norepinephrine in patients undergoing lung transplantation(0-72 hours (0-3 days) after lung transplantation)
- To determine whether cytokine reduction by cytokine filtration improves forced expiratory volume (FEV1), forced vital capacity (FVC), and total lung capacity in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration improves levels of plasma inflammatory markers (including cytokines) in patients undergoing lung transplantation.(0-72 hours (0-3 days) after lung transplantation)
- To determine whether cytokine reduction by cytokine filtration decreases severity of primary graft dysfunction (PGD) in patients undergoing lung transplantation(0-72 hours (0-3 days) after lung transplantation)
- To determine whether cytokine reduction by cytokine filtration decreases incidence of primary graft dysfunction (PGD) in patients undergoing lung transplantation(0-72 hours (0-3 days) after lung transplantation)
- To determine whether cytokine reduction by cytokine filtration improves diffusion capacity of the lungs (DLCO) in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration decreases lung infiltrates and oedema in patients undergoing lung transplantation(0-72 hours (0-3 days) after lung transplantation)
- To determine whether cytokine reduction by cytokine filtration improves occurrence of any acute rejection episodes in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration improves Chest CT in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration improves presence of any CLAD in patients undergoing lung transplantation(First 4 years)
- To determine whether cytokine reduction by cytokine filtration improves kidney function in patients undergoing lung transplantation(First 4 years)
研究者
Sandra Lindstedt
Professor
Lund University Hospital